Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:LPCN

Lipocine Q4 2025 Earnings Results & Report

Lipocine logo
$1.68 +0.06 (+3.40%)
As of 02:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lipocine beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 10, 2026. The company reported EPS of -$0.34 versus the -$0.60 consensus estimate, while revenue of $1.15 million topped the $0.12 million estimate by $1.03 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Lipocine EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.26
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Lipocine Revenue Results

Actual Revenue
$1.15 million
Expected Revenue
$0.12 million
Beat/Miss
Beat by +$1.03 million
YoY Revenue Growth
N/A

Upcoming Earnings

Lipocine's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Lipocine's Q4 2025 Press ReleasePress Release
(8-K)
Lipocine's Q4 2025 Annual reportAnnual report
(10-K)

Lipocine Q4 2025 Earnings FAQ

Lipocine (NASDAQ:LPCN) reported earnings of -$0.34 per share for Q4 2025, beating the consensus estimate of -$0.60. The report was announced on Tuesday, March 10, 2026.

Lipocine reported revenue of $1.15 million for Q4 2025, against a consensus estimate of $0.12 million.

Lipocine's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lipocine on the company's earnings history page.

Lipocine Earnings Headlines

Lipocine (NASDAQ: LPCN) wins Health Canada approval for TLANDO in Canada
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101192
Lipocine Announces Health Canada Approval of TLANDO(R) for Testosterone Replacement Therapy
October 8, 2026  |  marketscreener.comM
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel
October 14 at 1:00 AM  |  Brownstone Research (Ad)
Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy
October 8, 2026  |  marketscreener.comM
Lipocine stock surges 30% on Health Canada drug approval
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lipocine-stock-surges-30-health-132454369.html
3 Penny Stocks to Watch Today, October 8
October 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/3-penny-stocks-to-watch-today-october-8?utm_source=marketbeat.com&utm_medium=referral
See More Lipocine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lipocine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipocine and other key companies, straight to your email.

About Lipocine

Lipocine (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of poorly bioavailable compounds, with the goal of offering alternatives to injectable or otherwise inconvenient treatments.

Lipocine’s development programs have included oral hormone-replacement therapies, treatments for central nervous system disorders, and therapies for metabolic and liver-related conditions. Its lead product, TLANDO (testosterone undecanoate), was approved by the U.S. Food and Drug Administration in 2022 as an oral testosterone-replacement therapy for adult males with conditions associated with a deficiency or absence of endogenous testosterone.

Based in Salt Lake City, Utah, Lipocine has historically focused primarily on the U.S. pharmaceutical market while advancing its pipeline through clinical development and commercial partnerships. The company is led by Mahesh Karande, who has served as its president and chief executive officer. Lipocine continues to evaluate and develop additional candidates based on its oral drug-delivery platform.

View Lipocine Profile
Earnings Tools